Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil

Drug Metabolism and Disposition

Volumn 37, Issue 12, 2009, Pages 2349-2358

  Bergman, Ebba ^a   Lundahl, Anna ^a   Fridblom, Patrik ^b   Hedeland, Mikael ^a,c   Bondesson, Ulf ^a,c   Knutson, Lars ^b   Lennernäs, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c NATIONAL VETERINARY INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GEMFIBROZIL; ROSUVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG BILE LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INHIBITION; DRUG TRANSPORT; FEMALE; FEMORAL VEIN; HEPATIC DUCT; HEPATIC VEIN; INTRAJEJUNAL DRUG ADMINISTRATION; MALE; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; SWINE;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BILE; CYCLOSPORINE; ENTEROHEPATIC CIRCULATION; FEMALE; FLUOROBENZENES; GEMFIBROZIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; JEJUNUM; LIVER; MALE; MICROSOMES, LIVER; MODELS, BIOLOGICAL; ORCHIECTOMY; PYRIMIDINES; SULFONAMIDES; SWINE;

SUIDAE; TIPULA IRIDESCENT VIRUS;

EID: 71049154560     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.029363     Document Type: Article

References (42)

1. Anzenbacher P, Soucek P, Anzenbacherová E, Gut I, Hrubý K, Svoboda Z, and Květina J (1998) Presence and activity of cytochrome P450 isoforms in minipig liver microsomes: comparison with human liver samples. Drug Metab Dispos 26:56-59. (Pubitemid 28071325)
2. Baranová J, Anzenbacherová E, Anzenbacher P, and Soucek P (2005) Minipig cytochrome P450 2E1: comparison with human enzyme. Drug Metab Dispos 33:862-865. (Pubitemid 40686641)
3. Bergman E, Forsell P, Tevell A, Persson EM, Hedeland M, Bondesson U, Knutson L, and Lennernäs H (2006) Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. Eur J Pharm Sci 29:205-214. (Pubitemid 44602407)
4. Böhme M, Müller M, Leier I, Jedlitschky G, and Keppler D (1994) Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver. Gastroenterology 107:255-265. (Pubitemid 24195369)
5. Cattaneo D, Zenoni S, Murgia S, Merlini S, Baldelli S, Perico N, Gotti E, Ottomano C, Crippa A, and Remuzzi G (2005) Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients: not simply overestimation. Clin Chim Acta 355:153-164. (Pubitemid 40501143)
6. Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M, Kuwano M, and Akiyama SI (1999) Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol 56:1219-1228. (Pubitemid 29352317)
7. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, and Cantarini MV (2002) The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 58:527-531.
8. Deters M, Kirchner G, Koal T, Resch K, and Kaever V (2004) Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats. Dig Dis Sci 49:30-37. (Pubitemid 38183741)
9. Deters M, Nolte K, Kirchner G, Resch K, and Kaever V (2001) Comparative study analyzing effects of sirolimus-cyclosporin and sirolimus-tacrolimus combinations on bile flow in the rat. Dig Dis Sci 46:2120-2126. (Pubitemid 32955220)
10. Dollery C (1999) Therapeutic Drugs, 2nd ed. Vol.1, pp G34-G37, Churchill Livingstone, Edinburgh.
11. Eisenblätter T and Galla HJ (2002) A new multidrug resistance protein at the blood-brain barrier. Biochem Biophys Res Commun 293:1273-1278.
12. Fujino H, Saito T, Tsunenari Y, Kojima J, and Sakaeda T (2004) Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica 34:961-971. (Pubitemid 40070099)
13. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, et al. (2007) Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 81:362-370. (Pubitemid 46364477)
14. Goh LB, Spears KJ, Yao D, Ayrton A, Morgan P, Roland Wolf C, and Friedberg T (2002) Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem Pharmacol 64:1569-1578. (Pubitemid 35333418)
15. Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, Ross DD, and Mao Q (2006) Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 58:374-383. (Pubitemid 43800742)
16. Hagenbuch B and Gui C (2008) Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38:778-801.
17. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, and Kim RB (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793-1806.
18. Huang L, Wang Y, and Grimm S (2006) ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34:738-742.
19. Kararli TT (1995) Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 16:351-380.
20. Kitamura S, Maeda K, Wang Y, and Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36:2014-2023. (Pubitemid 351574837)
21. Lampen A, Christians U, Guengerich FP, Watkins PB, Kolars JC, Bader A, Gonschior AK, Dralle H, Hackbarth I, and Sewing KF (1995) Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 23:1315-1324. (Pubitemid 26007838)
22. Loor R, Pope L, Boyd R, Wood K, and Bodepudi V (2004) Monitoring cyclosporine of pre-dose and post-dose samples using nonextraction homogeneous immunoassay. Ther Drug Monit 26:58-67. (Pubitemid 38140913)
23. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
24. Martin PD, Warwick MJ, Dane AL, Brindley C, and Short T (2003a) Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 25:2553-2563. (Pubitemid 37373930)
25. Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, and Lenz E (2003b) Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 25:2822-2835. (Pubitemid 37510592)
26. Nordgren A, Karlsson T, and Wiklund L (2002) Glutamine concentration and tissue exchange with intravenously administered alpha-ketoglutaric acid and ammonium: a dose-response study in the pig. Nutrition 18:496-504. (Pubitemid 34586805)
27. Persson EM, Nordgren A, Forsell P, Knutson L, Öhgren C, Forssén S, Lennernäs H, and Abrahamsson B (2008) Improved understanding of the effect of food on drug absorption and bioavailability for lipophilic compounds using an intestinal pig perfusion model. Eur J Pharm Sci 34:22-29.
28. Persson EM, Nordgren A, Forsell P, Knutson L, Öhgren C, Zacchari H, Abrahamsson B, Lernnernäs H (2007) Is there an effect of food on the biliary secretion of cyclosporine and three in vivo formed metabolites in a porcine model? J Drug Del Sci Techol 17:253-258. (Pubitemid 47395776)
29. Petri N, Bergman E, Forsell P, Hedeland M, Bondesson U, Knutson L, and Lennernäs H (2006) First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. Drug Metab Dispos 34:1182-1189. (Pubitemid 43920879)
30. Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, and Lin JH (2002) Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30:1280-1287. (Pubitemid 35265837)
31. Sallustio BC, Fairchild BA, Shanahan K, Evans AM, and Nation RL (1996) Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. Drug Metab Dispos 24:984-989. (Pubitemid 26314550)
32. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, and Raza A (2004) The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75:455-463.
33. Shitara Y, Hirano M, Sato H, and Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228-236. (Pubitemid 39287802)
34. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, and Schneck DW (2004) Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76:167-177. (Pubitemid 39013406)
35. Sjödin E, Fritsch H, Eriksson UG, Logren U, Nordgren A, Forsell P, Knutson L, and Lennernäs H (2008) Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs. Drug Metab Dispos 36:1519-1528.
36. m): accuracy and robustness evaluated through experimental data and Monte Carlo simulations. Drug Metab Dispos 37:47-58.
37. Tang H, Pak Y, and Mayersohn M (2004) Protein expression pattern of P-glycoprotein along the gastrointestinal tract of the Yucatan micropig. J Biochem Mol Toxicol 18:18-22. (Pubitemid 38312718)
38. Thompson PD, Clarkson P, and Karas RH (2003) Statin-associated myopathy. JAMA 289:1681-1690.
39. Upton RN (2008) Organ weights and blood flows of sheep and pig for physiological pharmacokinetic modelling. J Pharmacol Toxicol Methods 58:198-205.
40. Watanabe T, Kusuhara H, Maeda K, Shitara Y, and Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652-662.
41. Xia CQ, Liu N, Miwa GT, and Gan LS (2007) Interactions of cyclosporin a with breast cancer resistance protein. Drug Metab Dispos 35:576-582. (Pubitemid 46513259)
42. Zaïr ZM, Eloranta JJ, Stieger B, and Kullak-Ublick GA (2008) Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics 9:597-624. (Pubitemid 351803919)